Cure8 research brief
This analysis directly addresses treatments commonly used for perianal fistulizing Crohn’s disease and compares biologic anti-TNF drugs with emerging mesenchymal stem cell therapy, information that could affect treatment choices and research priorities.
Adults with perianal fistulizing Crohn’s disease, gastroenterologists and colorectal surgeons treating PFCD, clinical researchers studying biologics or stem-cell therapies, and patients weighing fistula-focused versus systemic remission outcomes.
The study combined 15 randomized controlled trials (2,475 patients) to compare outcomes for fistula remission, fistula response, and clinical remission, and to assess adverse events and infections.
MSCs showed the largest effect sizes and top SUCRA rankings for fistula healing outcomes, whereas anti-TNF therapies showed superior odds for achieving clinical remission. The authors note these are indirect comparisons and call for direct head-to-head trials to confirm comparative effectiveness.
How to use this: If you or your clinician are considering treatment options for perianal fistulizing Crohn’s disease, this paper suggests MSCs may perform particularly well for fistula healing whereas anti-TNF drugs remain effective for broader clinical remission.
Treatment decisions should still rely on individualized clinical factors, availability, and guideline recommendations.
The report is a network meta-analysis of randomized trials using indirect comparisons; the authors caution that head-to-head randomized trials are needed to confirm whether MSCs are truly superior to anti-TNF agents for fistula healing. The article is an abstract/full-text from Frontiers in Immunology (2026).
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Early “top-down” infliximab plus an immunomodulator was linked to much lower 5-year risk of abdominal surgery, disease progression, and hospitalization versus a step-up approach. This could influence treatment planning...
Perianal fistulizing Crohn's disease is a disabling complication; a subcutaneous form of infliximab could lower treatment burden and expand options if its effectiveness and safety in this specific setting are confirmed.
Biologics and newer small molecules have markedly changed IBD care and outcomes for many patients, but their population-level impact depends on access, cost, and how they are used. Understanding this helps patients and...
